常见驱动基因阳性非小细胞肺癌的靶向治疗  

Targeted therapy of common driver gene-positive non-small cell lung cancer

作　　者：周飞[1] 陈越 胡舒怡 沈波[1] 方瑛 周国仁[1] ZHOU Fei;CHEN Yue;HU Shuyi;SHEN Bo;FANG Ying;ZHOU Guoren(Department of Medical Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing,Jiangsu 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院江苏省肿瘤医院江苏省肿瘤防治研究所肿瘤内科,江苏南京210009

出　　处：《中国临床研究》2025年第3期335-338,344,共5页Chinese Journal of Clinical Research

基　　金：国家自然科学基金面上项目(82273162);江苏省卫生健康委员会科研重点项目(ZD2021019)。

摘　　要：肺癌是发病率最高的恶性肿瘤,非小细胞肺癌(NSCLC)是肺癌最主要的病理类型。驱动基因的发现及靶向药物的发展对NSCLC患者的治疗产生了重要影响。目前临床上有效的驱动基因靶向治疗主要是针对表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)、c-ros原癌基因1(ROS1)等。EGFR酪氨酸激酶抑制剂(EGFR-TKI)和ALK-TKI被纳入EGFR突变、ALK融合突变的晚期NSCLC患者的标准一线治疗。本文将对这三种驱动基因靶向治疗的相关研究进行综述。Lung cancer is the most common malignant tumor,and non-small cell lung cancer(NSCLC)is the major pathological type of lung cancer.The discovery of driver genes and the development of targeted drugs showed an important impact on the treatment of NSCLC patients.Currently,clinically effective driver gene targeted therapy mainly targets epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK),and c-ros oncogene 1(ROS1).EGFR tyrosine kinase inhibitors(EGFR-TKI)and ALK-TKI were included in standard first-line treatment for advanced NSCLC patients with EGFR mutations and ALK fusion mutations.This article reviews the relevant research on these three driver genes and their targeted therapy.

关 键 词：非小细胞肺癌 驱动基因 靶向治疗 表皮生长因子受体 间变性淋巴瘤激酶 c-ros原癌基因1 酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]